Jennerex enrolls first patient in phase IIb liver cancer trial

Friday, November 4, 2011

Jennerex has initiated enrollment and the first patient hasbeen randomized in a phase IIb clinical trial called TRAVERSE. The trialis evaluating the use of JX-594 to treat patients with advanced livercancer, also known as hepatocellular carcinoma (HCC), who failed priortherapy with sorafenib (NexavarR), the only approved drug for advancedHCC. In addition, Jennerex earned a milestone payment from itsdevelopment and commercialization partner, Transgene, based on therandomization of the first patient in the TRAVERSE clinical trial.

The TRAVERSE phase IIb clinical trial is designed to enroll 120 patientswith advanced liver cancer who have failed sorafenib therapy. Therandomized study will be conducted at approximately 45 sites worldwideincluding North America, South Korea, Taiwan, Hong Kong, and Europe. Theprimary objective of the trial is to determine the overall survivalbenefit for patients receiving JX-594 with best supportive care, comparedto best supportive care alone in patients with refractory advanced livercancer.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news,
emerging trends, and business issues around everything in the rapidly changing clinical research
marketplace. Check out our new CWWeekly page! Sign up today for your
free email newsletter, update your bookmarks and check us out regularly!
We look forward to bringing you the best news and information about
clinical research in 2018!